Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 96

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 96
---
 resources to their marketing and distribution; |

| ● | the collaborator may not properly maintain or defend our IP                                                                           
 rights or may use our IP or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize 
 or invalidate our IP or proprietary information or expose us to potential liability;                                                  |

| ● | disputes may arise between us and the collaborator that cause                                                                         
 the delay or termination of the research, development or commercialization of our drug and diagnostics technology candidates, or that 
 result in costly litigation or arbitration that diverts management attention and resources;                                           |

| ● | the collaboration may be terminated and, if terminated, may                                                                             
 result the Company needing additional capital to pursue further development or commercialization of the applicable drug and diagnostics 
 technology candidates;                                                                                                                  |

52

| ● | the collaborator may own or co-own IP covering our drugs that                                                                
 results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such IP; |

| ● | the collaboration may result in increased operating expenses     
 or the assumption of indebtedness or contingent liabilities; and |

| ● | the collaboration arrangement may result in the loss of key                        
 personnel and uncertainties in our ability to maintain key business relationships. |

As a result, if we enter into collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the benefit of such transactions, which could delay our timelines or otherwise adversely affect our business. Following a strategic transaction or license, we may not achieve the revenue or specific net income that justifies such transaction. If we are unable to reach agreements with a suitable collaborator on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug or diagnostics technology candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we fail to enter into collaborations, we may seek to fund and undertake development or commercialization activities on our own, but we may not have sufficient funds or expertise to undertake the necessary development and commercialization activities. In such a case, we may not be able to further develop our drug and diagnostics technology candidates or bring them to market and generate product sales revenue, which would harm our business prospects, financial condition and results of operations. Our employees, independent contractors, consultants, commercial partners